Is Qiagen NV (QGEN) a risky stock?
As of July 24, 2026, Clavix grades Qiagen NV (QGEN) A- for risk, a composite score of 84 out of 100 on an A+ to F scale, which puts QGEN in the "low risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 24, 2026. Clavix regrades every trading day.
The five risk dimensions behind QGEN's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how QGEN scores on each, as of July 24, 2026.
What's moving QGEN's risk right now
Company-specific signals Clavix flags behind QGEN's current grade, drawn from recent news and filings as of July 24, 2026.
KKR's reported interest in acquiring Qiagen and a new stake from Y Intercept Hong Kong are drawing attention back to the stock. A separate rating piece points to roughly 7% upside, though no deal has been confirmed.
Reports suggest a potential $50 per share acquisition bid for Qiagen, which would be a meaningful premium and could act as a floor for the stock. Major private equity firms appear to see value despite weaker performance this year.
A growing U.S. Cyclospora outbreak is pulling in orders for Qiagen's molecular diagnostic tests from public health and reference labs. The outbreak gives a modest lift to near-term revenue and raises the profile of its infectious disease products.
Recent QGEN news
The latest headlines Clavix ingested for Qiagen NV, newest first. These feed the news-sentiment dimension of QGEN's grade.
-
KKR is in focus after being linked to potential takeover interest in Qiagen (QGEN) and announcing Allyntra, a new precision engineered medtech platform, though KKR's share price has declined 25.89% YTD and posted a 35.14% 1-year total shareholder return.
-
KKR has launched Allyntra, a medtech platform for advanced surgical technologies, while pursuing a controlling stake in Portuguese fiber operator DStelecom. The firm has also been identified as a potential bidder in early takeover discussions for Qiagen (QGEN).
What a A- grade means
On the Clavix A+ to F scale, QGEN's composite of 84 falls in the A band (80–100), read as "low risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell QGEN or any security. Grades are risk indicators, not predictions of return. Data may be delayed.